Ekso Bionics Holdings, Senomyx, ChromaDex, Sierra Oncology and Novelion Therapeutics topped last week’s NASDAQ biotech stock list.
Data from the P&S Market Research indicated the already lucrative global animal pharmaceutical market, valued at $12,614.3 million total in 2015, will increase at a CAGAR of 7.7 percent by 2022.
Collegium Pharmaceutical, Depomed, Xoma, ChromaDex and Ophthotech topped last week’s NASDAQ biotech stock list.
Sierra Oncology, Iradimed, Accuray, Novan and KalVista Pharmaceutical topped last week’s NASDAQ biotech stock list.
MassRoots is going after major changes after its board of directors fired founder and CEO Isaac Dietrich.
Infinity Pharmaceuticals, Sorrento Therapeutics, CASI Pharmaceuticals, KalVista Pharmaceuticals, and Prima BioMed topped last week’s NASDAQ biotech stock list.
Here, the Investing News Network provides a breakdown of how to invest in cardiovascular disease treatments and what the market outlook looks like.
Pharmaceutical companies work towards achieving the goal of bringing new cures or treatments to the market and improve the treatment available for patients.
Zogenix, Aradigm, Vermillion, Aralez Pharmaceuticals and Kura Oncology top the NASDAQ biotech stock list.
The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
Neovasc, Adaptimmune, Curis, Vericel and MannKind top the NASDAQ biotech stock list.